{
  "id": 14350367,
  "title": "Earnings call transcript: EBR’s Q3 2026 revenue miss sparks sharp selloff",
  "url": "https://urgent.news/2026/10/14/earnings-call-transcript-ebrs-q3-2026-revenue-miss-sparks-sharp",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T02:09:10.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-ebrs-q3-2026-revenue-miss-sparks-sharp-selloff-93CH-4947880"
  },
  "original_language": "en",
  "account": "EBR reported Q3 revenue of $3.5 million, falling short of the $4.7 million forecast. The shortfall occurred as the company intentionally slowed some commercial activity to rework its sales strategy and field organization. This move led to a sharp pre-market drop of 40.43%, with the stock price falling from $0.235 to $0.14. Following the report, the stock traded at $0.16, up 3.23% from the prior close.\n\nThe lack of EPS data in the call means a direct earnings-per-share comparison is not possible. Analysts had expected a loss of $0.0346 per share. The revenue miss came in at $3.5 million, missing the forecast by 25.53%. Management cited Q3 implants and procedure growth as below expectations, noting a shift from broad site expansion to deeper penetration of existing accounts. Leadership changes and field realignment also impacted near-term commercial performance.\n\nLong-term positives for EBR include clinical support, regulatory progress, and new manufacturing capacity. The company completed 40 WiSE procedures in Q3 and reached 157 cumulative commercial implants since launch. Management indicated that while the technology continues to show strong clinical results, commercial execution lagged due to reduced physician training, site activation, and broader territory coverage.\n\nThe stock's sharp decline reflects a strong negative reaction to the revenue miss and the weaker-than-expected commercial trend. InvestingPro analysis suggests the stock has entered oversold territory, though fundamental execution concerns remain. The stock currently trades near the bottom of its 52-week range of $0.13 to $1.47, indicating caution among investors. No trading volume data was provided, but the size of the pre-market decline suggests investors were focused on near-term execution risks rather than the company's long-term potential.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Earnings call transcript: Core Lithium Q1 2026 shares fall as restart advances",
        "url": "https://urgent.news/2026/10/14/earnings-call-transcript-core-lithium-q1-2026-shares-fall-as-restart",
        "published": "2026-10-14T01:28:45.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}